Dr. Lajos Pusztai is a Professor of Medicine at Yale University and Scientific Co-Director of the Breast Center. He has made crucial contributions to gene expression profiling for predicting therapy response, and has led numerous clinical trials investigating novel therapies, including immunotherapies for breast cancer. Dr. Pusztai is among the top 1% most highly cited clinical investigators.

Dr. Esteva currently serves as the Chief of the Division of Hematology and Medical Oncology at Lenox Hill Hospital in New York City. and is also a Professor of Medicine at the Zucker School of Medicine. With over 25 years of experience, he has made significant contributions to breast cancer research, particularly in HER2-targeted therapies and overcoming treatment resistance. Dr. Esteva has authored more than 200 peer-reviewed publications and is recognized for his innovative clinical trials and translational research. His expertise and leadership in the field have earned him several accolades, including election to the American Society for Clinical Investigation and fellowship in the American College of Physicians.

Dr. Freya R. Schnabel serves as the Director of Breast Surgery at NYU Langone Health’s Perlmutter Cancer Center, specializing in breast cancer risk assessment, risk-reducing strategies, and advancing surgical techniques. She oversees vital research efforts on clinical outcomes and patient care. Recognized multiple times by New York Magazine as one of the city’s Best Doctors, Dr. Schnabel is also involved in cutting-edge research on molecular techniques and surgical technologies that enhance precision and reduce the need for re-operations.

Dr. Adam M. Brufsky is a Professor of Medicine at the University of Pittsburgh School of Medicine and serves as the Associate Chief of Hematology/Oncology. Dr. Brufsky is also the Medical Director of the Magee-Women's Cancer Program and the Associate Director for Clinical Investigation at UPMC Hillman Cancer Center. With over 25 years of experience, he has made significant contributions to breast cancer research, particularly in clinical trials for metastatic breast cancer. Dr. Brufsky has authored numerous research articles in high-impact journals and is recognized for his innovative work in increasing community access to clinical trials.

Dr. Elzbieta Senkus-Konefka is an Associate Professor at the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland. She specializes in breast cancer, with a focus on high-risk patients and special phenotypes. Dr. Senkus-Konefka has played a key role in developing international guidelines for early and metastatic breast cancer as the Section Editor of the ESMO Guidelines Committee (2015-2020). She has published over 150 peer-reviewed articles, contributed to 21 book chapters, and is a member of multiple prestigious committees, including the EORTC Breast Cancer Group and the European Breast Cancer Conference.

Dr. Robert Schneider is the Albert Sabin Professor of Molecular Pathogenesis at NYU School of Medicine and Co-Director of the Breast Cancer Program at NYU Cancer Institute. His research focuses on the mechanisms behind breast cancer metastasis and the development of new therapeutic strategies to improve patient outcomes. Dr. Schneider has authored over 140 peer-reviewed papers and received numerous accolades, including the Judah Folkman Memorial Lecture and the Susan E. Donelan Hope for the Future Award. He is also a founding scientist of five biotechnology companies translating oncology research into clinical applications.